Acasti Pharma (ACST) News Today C$0.58 +0.01 (+1.75%) (As of 03/27/2023) Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period OTC Markets Hosts Virtual Investor Presentation with Prashant Kohli, CEO of Grace Therapeutics (Acasti Pharma), with John Vandermosten, Senior Analyst at Zacks SCROctober 29, 2024 | msn.comLife Sciences Virtual Investor Forum Agenda Announced for September 19thSeptember 16, 2024 | finance.yahoo.comACST Stock Earnings: Acasti Pharma Beats EPS for Q1 2025August 9, 2024 | markets.businessinsider.comAcasti Pharma Inc. (ACST)April 6, 2024 | finance.yahoo.comAcasti Pharma Inc. Class AMarch 14, 2024 | edition.cnn.comAcasti Pharma (ACST) Price Target Increased by 200.00% to 6.12February 25, 2024 | msn.comAcasti Announces Third Fiscal Quarter 2024 Financial Results and Business HighlightsFebruary 12, 2024 | finance.yahoo.comWill Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?December 25, 2023 | finance.yahoo.comAcasti Pharma (ACST) Earnings Dates & ReportsNovember 14, 2023 | investing.comAcasti Pharma Inc Class A ACSTNovember 11, 2023 | morningstar.comWhy Acasti Pharma (ACST) Stock Is Exploding HigherSeptember 26, 2023 | benzinga.comAcasti to Participate in the H.C. Wainwright Global Investment ConferenceSeptember 6, 2023 | technews.tmcnet.comAcasti Pharma, Inc.: Acasti Announces First Quarter 2024 Financial Results and Business HighlightsAugust 11, 2023 | finanznachrichten.deAcasti Pharma Inc.: Acasti Pharma Reports Fiscal Year 2023 Operational ResultsJune 23, 2023 | finanznachrichten.deAcasti Pharma Reports Fiscal Year 2023 Operational ResultsJune 23, 2023 | finance.yahoo.comAcasti Announces Appointment of New Scientific Advisory Board MembersJune 22, 2023 | finance.yahoo.comACST - Acasti Pharma Inc.June 20, 2023 | sg.finance.yahoo.comClosing Bell: Acasti Pharma Inc up on Monday (ACST)April 7, 2023 | theglobeandmail.comAcasti Pharma announces CEO transitionApril 4, 2023 | seekingalpha.comAcasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange | MorningstarMarch 16, 2023 | morningstar.comAcasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare ConferenceMarch 8, 2023 | finance.yahoo.comWe're Hopeful That Acasti Pharma (CVE:ACST) Will Use Its Cash WiselyMarch 4, 2023 | finance.yahoo.comAcasti Pharma Recognizes Rare Disease DayMarch 1, 2023 | finance.yahoo.comHas Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?February 28, 2023 | msn.comAcasti Pharma to Present at Sidoti Virtual Investor Conference on January 18January 13, 2023 | benzinga.comAcasti Pharma Inc. (ACST) Q2 2023 Earnings Call TranscriptNovember 15, 2022 | seekingalpha.comAcasti Pharma to Present at Q4 Investor SummitNovember 9, 2022 | it.tmcnet.comAcasti Pharma to Report Second Quarter 2023 FinancialNovember 8, 2022 | tmcnet.comAcasti Pharma: Top 10 Undervalued Biotechnology Industry Sector Stocks on TSX Venture Exchange (ACST)September 17, 2022 | theglobeandmail.comAcasti Pharma to Participate in the Lytham Partners Fall 2022 Investor ConferenceSeptember 14, 2022 | finance.yahoo.comAcasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company's Drug Candidate for the Treatment of Ataxia TelangiectasiaSeptember 13, 2022 | it.tmcnet.comAcasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic NeuralgiaJuly 27, 2022 | finance.yahoo.comStock Day Media: Acasti Pharma Inc. Discusses Year-End Results and Clinical Development Progress with The Stock Day PodcastJuly 9, 2022 | finanznachrichten.deAcasti Pharma Inc. Discusses Year-End Results and Clinical Development Progress with The Stock Day PodcastJuly 7, 2022 | finance.yahoo.comAcasti Pharma, Inc. (ACST) CEO Jan D'Alvise on Q4 2022 Results - Earnings Call TranscriptJune 21, 2022 | seekingalpha.comAcasti Pharma reports GAAP EPS of $0.27 for FY2022June 21, 2022 | seekingalpha.comAcasti Pharma Inc. Retains Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication ProgramMay 23, 2022 | stockhouse.comAcasti Pharma CEO to Present at Microcap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 16thMay 12, 2022 | apnews.comAcasti Pharma CEO to Present at the 32nd Annual Oppenheimer Healthcare Conference on March 16thMarch 9, 2022 | finance.yahoo.comAcasti Pharma Schedules Third Quarter Fiscal 2022 Business Update Conference CallFebruary 7, 2022 | finance.yahoo.comThinking about buying stock in Naked Brand, Biondvax Pharmaceuticals, eMagin Corp, Red Cat, or Acasti Pharma?December 22, 2021 | benzinga.comAcasti Pharma CEO to Participate in the Benzinga All Access Event on December 2ndNovember 24, 2021 | finance.yahoo.comAcasti Pharma Schedules Second Quarter Fiscal 2022 Business Update Conference CallNovember 4, 2021 | finance.yahoo.comAcasti Pharma outlines key benefits of recent Grace Therapeutics acquisitionOctober 8, 2021 | proactiveinvestors.comAcasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in JapanOctober 6, 2021 | finance.yahoo.comAcasti Pharma Announces Initiation Of Pharmacokinetic Bridging Study For GTX-104September 29, 2021 | benzinga.comWhy Shares of Acasti Pharma Slumped TuesdayAugust 31, 2021 | msn.comAcasti Says 8-For-1 Reverse Stock Split Will Be implemented To Help Regain Nasdaq ComplianceAugust 28, 2021 | benzinga.com Get Acasti Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter. Email Address 70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today! (Ad)Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << ACST Media Mentions By Week ACST Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACST News Sentiment▼0.000.60▲Average Medical News Sentiment ACST News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACST Articles This Week▼00▲ACST Articles Average Week Get Acasti Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Graphite One News Today EQ News Today CI Canadian Convertible Bond ETF Common News Today BioRem News Today Moneta Gold News Today Canadian Gold News Today Aeterna Zentaris News Today Relevant Gold News Today Ascendant Resources News Today Niobay Metals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (CVE:ACST) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredThis is the worst sign for the U.S. stock market in 50 yearsThe Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts no...Stansberry Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this ...Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acasti Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acasti Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.